Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma

    September 2004 in “ Clinical cancer research ”
    Tanya Ahmad, Tim Eisen
    Studysummary In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clincancerres.aacrjournals.org →
    Discuss this study in the Community →